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alternative donors has been associated with increased graft
failure, graft versus host disease (GVHD), and transplant-
related mortality (TRM). HSCT using alternative donors with
post-transplantation cyclophosphamide (PT/Cy) has been
performed for hematologic malignancies with engraftment,
GVHD, and TRM comparable to that seen with HLA-matched
related donors. There are limited reports of HSCT in non-
malignant disorders using alternative donors and PT/Cy.
Design: We transplanted 9 patients with non-malignant
conditions (CGD¼3, DKC¼2, DBA¼1, HyperIgM¼1, XIAP¼1,
IPEX¼1) using an alemtuzamab/ﬂudarabine based reduced
intensity conditioning (RIC). All patients received GVHD
prophylaxis with PT/Cy, with the addition of mycophenolate
mofetil and tacrolimus for HSCT with haploidentical donors
and for alkylator-sensitive diagnoses (DKC). Six patients had
10/10 HLA-matched unrelated donors, and 3 had HLA-hap-
loidentical related donors.
Results: All 9 patients successfully engrafted by day 30. Ul-
timately, all patients have had sustained donor engraftment
sufﬁcient to eliminate manifestations of their underlying
diseases. 6 of 9 patients are full donor chimeras off immu-
nosuppression,1 patient is a stablemixed donor chimera (76%
CD3+ T cells) off immunosuppression, 1 patient is a stable
mixed donor chimera on a calcineurin inhibitor (CNI), and 1
patient had secondary graft failure but was ultimately
retransplanted with myeloablative conditioning using the
same donor, resulting in full donor chimerism and elimina-
tion of disease. One patient developed Grade 1 and one pa-
tient Grade 2 acute GVHD, both treated successfully with
steroids and a CNI. Mild skin chronic GVHD developed in 1
patient, treated successfully with phototherapy. No serious
infections occurred and there was no TRM. 1 patient devel-
oped veno-occlusive disease, treated successfully with
deﬁbrotide. Disease-free survival is 89% with a median
follow-up of 14 months (6-30 months). The patient with
secondary graft failure is now disease-free after myeloa-
blative transplant, for an overall disease-free survival of 100%
at a median of 14 months follow-up (6-60 months). Overall
survival is 100%.
Conclusion: We have observed successful engraftment suf-
ﬁcient to eliminate manifestations of disease, limited GVHD,
and no TRM in 9 patients with nonmalignant disorders using
alternative donors, RIC, and PT/Cy. RIC HSCT with PT/Cy
shows promise for curing nonmalignant pediatric disorders,
and potentially eliminates the need for CNI use after MUD
BMT. Development of prospective clinical trials to conﬁrm
these observations is warranted.100
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Autologoushematopoietic stemcell transplantation (HSCT)of
gene-modiﬁed cells (gene therapy) has shown clinical beneﬁt
for ADA-SCID when combined with non-myeloablative con-
ditioning and enzyme replacement therapy (ERT) cessation.
In a Phase II study (2009-2012) closed to enrollment
(NCT00794508), patients received autologous CD34+ cells
modiﬁed with the MND-ADA g-retroviral vector after condi-
tioning with busulfan (4 mg/kg) and ERT cessation (n¼10).
Patients were treated between 3 months and 15 years of age
(median¼11.5 months) and follow-up ranges from 22-64
months. With the exception of the oldest patient (at 15y), all
others remain off ERTwith normalized PBMCADA activity. All
nine remaining off ERT show normal proliferative responses
to mitogens and three of nine were able to discontinue IVIg.
MND-ADA is detected in PBMC (0.1-2.6 VCN) and in gran-
ulocytes (0.01-0.3 VCN) at most recent visit. A new Phase I/II
trial was opened in May 2013 (NCT01852071) in which sub-
jects have received autologous CD34+ cells modiﬁed with a
self-inactivating lentiviral vector (EFS-ADA) after condition-
ing with busulfan (4 mg/kg) with ERT cessation at 30 days
post-transplant (n¼6). Eight subjects have been enrolled at 4-
42monthsoldand the sixwhoarepast30days remainoff ERT.
The patients with the longest follow-up have normal or
higher PBMC ADA activity and good immune reconstitution.
Monitoring for insertional oncogenesis is on-going in both
studies and has not detected any monoclonal proliferative
events. These results demonstrate the efﬁcacy and safety of
autologous transplant/gene therapy for ADA SCID.101
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Background: In children, the therapeutic drug monitoring
(TDM) of intravenous (IV) busulfan (BU) in alloHCT can
Figure 1. Weibull model visualizing the relationship between busulfan
exposure and the probability of EFS (highest EFS rates at 75-100mg*h/L, HR ¼
0.37, 95% CI 0.15-0.92 compared to <50mg*h/L).
Figure 2. Weibull models visualizing the relationship between busulfan
exposure and EFS, by underlying disease.
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targets for exposure are however primarily based on adult
studies. Therefore, this study aimed to deﬁne the optimal
therapeutic target of BU in children and identify other patient-
speciﬁc variables to optimize outcomes following alloHCT.
Methods: This retrospective study utilized exposure-
response data available from routine pharmacokinetic anal-
ysis with or without TDM of BU levels in children and young
adults treated with HCT between the years of 2000-2013
from 13 different centers. Primary endpoints were event-free
survival (EFS) and overall survival (OS). Secondary endpoints
included treatment-related mortality (TRM), veno-occlusive
disease (VOD), acute graft-versus-host disease (aGVHD)
grade IIeIV and cGVHD. A predictor analysis using Cox
regression and multivariate Weibull models was performed.
Results: A total of 685 subjects (range 11-116 per center)
treated for a variety of malignant (n¼318) and non-malig-
nant disorders (n¼367), with a median age of 5.0 years
(range 0.1-28.7) were included in the analysis. The median
cumulative BU area-under-the-concentration-curve (AUC)
was 77mg*hr/L (range 21-160). In all patients, three-year
probability of EFS, OS and graft failurewas 72%, 79%, and 5.4%
respectively. BU AUC below 75 or above 100mg*hr/L
(p¼0.03), “ex-vivo T-cell depletion” (p¼0.02) and “in vivo T-
cell depletion using serotherapy” (ATG or alemtuzumab:
p¼0.02) were negative predictors of EFS. A U-shaped rela-
tionship between BU AUC & EFS was observed (Figure 1). In
patients with malignant disease optimal BU AUC was lower
compared to non-malignant disorders (83-95mg*hr/L vs
99-111 mg*h/L, p¼0.04, Figure 2). Below the optimal BU
target, the incidence of graft failure and relapse (malignant
only) was higher (p¼0.01), while above the target TRMincreased (p¼0.04). BU AUC above the median and addition
of melphalan were both independently associated with the
risk of aGvHD (p¼0.01, p¼0.04), and melphalan use further
increased the risk of VOD (p<0.01). No association was
found with cGvHD.
Conclusion: BU AUC targeted to a narrow therapeutic range,
which is indication dependent, (83-95 mg*h/L for malignant
and 99-111mg*h/L for non-malignant diseases) was found to
increase EFS andOS in children. Lower BUAUCwas associated
with graft-failure and relapse and higher BU AUC with TRM.
Our ﬁndings suggest that personalizing BU AUC by patient-
speciﬁc factors may improve efﬁcacy and reduce toxicity.102
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Stem cell transplantation for patients with non-malignant
disorders is often challenging,with frequent failure to engraft.
In the absence of an HLA-identical source, there is no
consensus about the best alternative hemopoietic stem cell
donor for patients who lack amatched sibling. Although cord
blood transplant has been a recent option for these patients,
an increased risk of viral infections and the potential for failed
engraftment have remained problematic and associated with
signiﬁcant mortality. We therefore studied 25 children who
underwent UCBT transplant at our institution for non-ma-
lignant disorders between 2007 and 2014. Their median age
was 8months (range, 2e66months) an their diagnoseswere:
SCID (n¼17), IPEX (n¼2), LAD (n¼1), Wiskott-Aldrich syn-
drome (n¼1), Krabbe (n¼1), mannosidosis (n¼1), HLH (n¼1),
and Diamond-Blackfan anemia (n¼1). Five patients had
persistent viral infections prior to transplant: RSV (n¼2),
Parainﬂuenza 3 (n¼1), VZV (n¼1) andNorovirus (n¼1), and 7
(30%) patients had required mechanical ventilation prior to
transplantation. Eight of 25 patients were 6/6 HLA antigen
matchedwith their cord stemcell donor, and17wereoneHLA
antigenmismatched.All patientsparticipated inaprospective
trial consisting of myeloablative conditioning using busulfan,
cyclophosphamide and ﬂudarabine without the use of sero-
therapy. The median total nucleated cell dose in the trans-
plant was 10x107 TNC/kg (range, 5.9e25.4). The median time
to neutrophil recovery was 19 days (range,8-30) and the
median time to platelet recoverywas 38 days (range, 26-127).
All but one evaluable patient achieved full donor chimerism
(deﬁned as> 95% donor cells in peripheral blood) by day +42.
The exception was a patient with Krabbe’s disease who is
nonetheless 60% donor chimeric at 6 months post-transplant
with normalization of enzyme levels. No severe aGVHD or
cGVHD has occurred and only one patient developed grade II
aGVHD (skin). All except the patient with HLH (who died of
